Raval Apexa, Trivedi Sunil
Indian J Exp Biol. 2016 Oct;54(10):619-629.
Deregulation of Insulin like growth factors (IGF) is an>important determinant of breast carcinogenesis. Circulatory IGF-1 (potent breast mitogen) and IGFBP-3 (its regulator) are exteisively evaluated; few studies report transcript copy numbers.(CN) from ex-vivo samples. This study from 106 patients evaluated mRNA expression (qRT-PCR CN) of IGF-1 and IGFBP-3 for prognostic and predictive utility from tumor, adjacent normal tissues (ANT) and lymph nodes. The differences in.IGF-1 and IGFBP-3 mRNA levels (CN/μg RNA) were juxtaposed to clinical and pathologic variables and survival. Tumors expressed lower IGF-1 and higher IGFBP-3 as compared to ANT. Both transcript levels decreased with increasing age. Primary tumors with nodal involvement, Invasive Lobular carcinoma (ILC) histology and stromal involvement showed increased transcript levels than their respective counterparts. Moreover, surviving patients showing no relapse had higher expression of both molecules. Early stage and necrosed tumors expressed higher IGFBP-3 while a trend of lower expression was seen as tumor grade advanced. IGF-1 expression was inversely correlated to stage, histologic grade and. Significantly different Relapse Free Survival (RFS) was seen with IGFBP-3 up-/down-regulation considering progesterone receptor (PR) status but not estrogen receptor (ER) and HER-2 while the Overall Survival (OS) was similar for both these molecules. We conclude that expression of these molecules may aid prognostication and success of anti IGF-1 strategies.
胰岛素样生长因子(IGF)失调是乳腺癌发生的重要决定因素。循环中的IGF-1(强效乳腺促有丝分裂原)和IGFBP-3(其调节因子)已得到广泛评估;很少有研究报道来自体外样本的转录本拷贝数(CN)。这项针对106名患者的研究评估了IGF-1和IGFBP-3的mRNA表达(qRT-PCR CN),以探讨其在肿瘤、邻近正常组织(ANT)和淋巴结中的预后和预测效用。将IGF-1和IGFBP-3 mRNA水平(CN/μg RNA)的差异与临床和病理变量及生存率进行了对比。与ANT相比,肿瘤中IGF-1表达较低,IGFBP-3表达较高。两种转录本水平均随年龄增长而降低。有淋巴结受累的原发性肿瘤、浸润性小叶癌(ILC)组织学类型和间质受累情况的转录本水平高于各自对应的情况。此外,无复发的存活患者这两种分子的表达较高。早期和坏死肿瘤中IGFBP-3表达较高,而随着肿瘤分级升高,有表达降低的趋势。IGF-1表达与分期、组织学分级呈负相关。考虑孕激素受体(PR)状态时,IGFBP-3上调/下调的无复发生存期(RFS)有显著差异,但雌激素受体(ER)和HER-2状态无差异,而这两种分子的总生存期(OS)相似。我们得出结论,这些分子的表达可能有助于预后评估及抗IGF-1策略的成功实施。